Oncology Market Value to More Than Double, Reaching USD 748.17 Billion by 2035

Over the past years, I have closely followed the evolution of the global oncology industry. What I have observed is steady, structural growth supported by science, policy support, and increasing healthcare demand. The oncology market is not expanding because of hype; it is expanding because cancer remains one of the most pressing global health challenges.

The global oncology market is valued at USD 279.98 billion in 2026, increasing from USD 251.01 billion in 2025, and is projected to reach USD 748.17 billion by 2035, growing at a CAGR of 11.54% between 2026 and 2035. These numbers reflect long-term demand, expanding treatment options, and sustained research investments.

This growth is grounded in real clinical need.

Metric	Details
Market Size in 2026	USD 279.98 Billion
Projected Market Size in 2035	USD 748.17 Billion
CAGR (2026 - 2035)	11.54%
Leading Region	North America share by 43%
Market Segmentation	By Therapy Type, By Cancer Type, By Modality, By End User, By Technology, By Region
Top Key Players	Roche Holding AG (Genentech), Merck & Co., Inc., Bristol-Myers Squibb (BMS), Pfizer Inc., Novartis AG, AstraZeneca plc, Johnson & Johnson (Janssen Oncology)

A sample made for you, zero cost, instant download: https://www.towardshealthcare.com/download-sample/5920

Understanding the Oncology Market

The oncology market includes cancer diagnostics, treatment therapies, and supportive care solutions. It covers pharmaceuticals such as chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. It also includes radiation therapy, surgical oncology, imaging technologies, molecular diagnostics, and liquid biopsy solutions.

In my experience, oncology is one of the most research-intensive segments in healthcare. Drug pipelines are deep, regulatory pathways are evolving, and technology integration is accelerating. Precision medicine has become central to treatment planning, and companion diagnostics are increasingly tied to therapy selection.

Cancer care today is more specialized and data-driven than it was even five years ago.

Key Market Growth Factors

Rising Cancer Incidence

One of the primary growth drivers is the increasing global burden of cancer. Aging populations, urban lifestyles, dietary changes, and environmental factors contribute to higher incidence rates. At the same time, improved screening programs are identifying more cases at earlier stages.

This naturally increases demand for diagnostics, therapies, and long-term management solutions.

Expansion of Precision Medicine

Precision oncology has moved from concept to clinical reality. Genomic testing, biomarker identification, and targeted biologics allow physicians to tailor treatment strategies based on tumor characteristics.

This improves patient outcomes and reduces unnecessary side effects. As diagnostic tools improve, the use of targeted therapies continues to expand across tumor types.

Strong Drug Development Pipeline

Oncology remains the largest therapeutic area in global drug development. Immune checkpoint inhibitors, CAR-T therapies, bispecific antibodies, and antibody-drug conjugates are advancing rapidly.

Major pharmaceutical companies continue to allocate significant R&D budgets toward oncology portfolios.

Segment Insights

Therapy Type

Pharmacological or drug-based therapy accounted for approximately 68% of the market share in 2024. These therapies are widely used across cancer stages and are often part of combination regimens.

Within this category, immunotherapy; including ICIs and CAR-T; is expected to record the fastest growth during the forecast period. These therapies offer more targeted immune activation and have demonstrated durable responses in certain cancers.

Cancer Type

Breast cancer held approximately 15% market share in 2024, making it the largest segment by cancer type. Increased screening programs and awareness initiatives have contributed to earlier diagnosis and higher treatment uptake.

Liver cancer is expected to grow at a faster rate in the coming years due to increasing incidence and growing investment in treatment innovation.

Modality

Therapeutic oncology accounted for around 72% share in 2024. Treatment-focused services and drug-based approaches continue to dominate expenditure.

However, diagnostic oncology is growing quickly. Liquid biopsy technologies, molecular diagnostics, and advanced imaging tools are gaining wider clinical acceptance, particularly for early-stage detection.

End User

Hospitals and cancer institutes held roughly 60% share of the global market in 2024. These institutions provide comprehensive care, including diagnostics, surgery, radiation, and systemic therapies.

Specialty oncology clinics are expanding rapidly, particularly in urban areas. Their focused expertise and streamlined patient management models are attracting patients seeking specialized care.

Technology

Monoclonal antibodies and targeted biologics represented approximately 36% of the technology segment in 2024. These therapies are widely adopted due to their tumor-specific mechanisms.

Immune checkpoint inhibitors are projected to grow at the highest rate, driven by ongoing clinical trial expansion and broader label approvals.

Regional Overview

North America

North America accounted for about 43% of global oncology market share in 2024. The United States continues to lead in clinical trials, regulatory approvals, and biotechnology innovation.

The U.S. oncology market is valued at USD 81.34 billion in 2025 and is projected to reach USD 211.78 billion by 2034, growing at a CAGR of 11.75%.

The region benefits from strong research institutions, advanced healthcare infrastructure, and high adoption of new therapies.

Asia Pacific

Asia Pacific is expected to be the fastest-growing region during the forecast period. Large populations in China and India, increasing healthcare access, and rising cancer incidence are driving demand.

Government investments in oncology infrastructure, clinical trials, and domestic drug development are strengthening regional growth.

Europe

Europe is witnessing steady expansion supported by research collaborations and targeted therapy adoption. Countries such as Germany and the UK are increasing investments in immunotherapy and precision medicine.

Policy support and funding initiatives are helping improve access to cancer medicines across the region.

Latin America and Middle East & Africa

Latin America is growing due to rising awareness, screening initiatives, and expanding oncology fellowship programs. Regulatory approvals are increasing access to newer therapies.

The Middle East & Africa region is benefiting from healthcare infrastructure expansion and supportive government policies aimed at improving cancer care systems.

Let's Explore Role of Major Industry Players

The oncology market is highly competitive and led by multinational pharmaceutical and biotechnology firms.

Companies such as Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb, Pfizer Inc., and Novartis AG maintain strong oncology portfolios across multiple tumor types.

Other important contributors include AstraZeneca plc, Johnson & Johnson, Amgen Inc., Gilead Sciences, and BeiGene Ltd..

In diagnostics and imaging, firms like Illumina, Inc. and Siemens Healthineers play an important role in enabling precision treatment strategies.

Strategic collaborations, licensing agreements, and acquisitions remain common as companies aim to strengthen their oncology pipelines.

Top 10 Powerhouse Medicines of Novartis with Core Benefits (2024)

Medicine Name	Core Benefits	Net Sales (USD millions, 2024)
Entresto	Oral medicine for heart failure and hypertension	7,822
Cosentyx	Injectable treatment for inflammatory and immune conditions	6,141
Kesimpta	Injectable treatment for relapsing multiple sclerosis	3,224
Kisqali	Oral treatment for a type of breast cancer	3,033
Promacta / Revolade	Oral treatment for certain blood disorders	2,216
Tafinlar + Mekinist	Oral combination targeted therapy for a certain type of cancer	2,058
Jakavi	Oral treatment for certain rare blood disorders	1,936
Tasigna	Oral treatment for a type of chronic myeloid leukemia	1,671
Xolair*	Injectable medicine for certain respiratory and immunological conditions (severe asthma)	1,643
Ilaris	Injectable medicine for certain rare autoinflammatory disorders	1,509

AI in Oncology

The AI in oncology market is estimated at USD 1.95 billion in 2024 and is projected to reach USD 25.02 billion by 2034, growing at a CAGR of 29.36%.

Artificial intelligence is being applied in medical imaging, pathology analysis, genomics interpretation, and treatment planning. It assists clinicians in improving diagnostic accuracy and identifying optimal therapy combinations.

AI tools are also being used to analyze large clinical datasets and support drug discovery efforts.

While still evolving, AI integration is becoming a practical component of oncology workflows rather than a theoretical concept.

Investment and Opportunity Outlook

Oncology continues to attract significant venture capital and institutional investment. Funding is directed toward cell and gene therapies, radiopharmaceuticals, antibody-drug conjugates, and liquid biopsy platforms.

Emerging markets present strong expansion opportunities due to unmet clinical needs and growing healthcare infrastructure.

Precision medicines and combination therapies are expected to remain major growth areas over the next decade.

What are the Market Challenges?

Despite strong growth, oncology faces challenges.

High treatment costs can limit accessibility, particularly in developing regions. Clinical development timelines are long and capital-intensive. Manufacturing complexities in cell therapies also present scalability concerns.

Reimbursement policies and pricing pressures continue to influence market dynamics.

Sustainable growth will depend on balancing innovation with affordability.